全文获取类型
收费全文 | 6248篇 |
免费 | 405篇 |
国内免费 | 37篇 |
专业分类
耳鼻咽喉 | 69篇 |
儿科学 | 92篇 |
妇产科学 | 150篇 |
基础医学 | 798篇 |
口腔科学 | 62篇 |
临床医学 | 680篇 |
内科学 | 1443篇 |
皮肤病学 | 75篇 |
神经病学 | 536篇 |
特种医学 | 228篇 |
外科学 | 997篇 |
综合类 | 39篇 |
预防医学 | 327篇 |
眼科学 | 204篇 |
药学 | 386篇 |
中国医学 | 5篇 |
肿瘤学 | 599篇 |
出版年
2024年 | 10篇 |
2023年 | 63篇 |
2022年 | 103篇 |
2021年 | 234篇 |
2020年 | 162篇 |
2019年 | 220篇 |
2018年 | 262篇 |
2017年 | 169篇 |
2016年 | 180篇 |
2015年 | 161篇 |
2014年 | 253篇 |
2013年 | 333篇 |
2012年 | 497篇 |
2011年 | 409篇 |
2010年 | 253篇 |
2009年 | 237篇 |
2008年 | 370篇 |
2007年 | 367篇 |
2006年 | 369篇 |
2005年 | 343篇 |
2004年 | 282篇 |
2003年 | 264篇 |
2002年 | 265篇 |
2001年 | 79篇 |
2000年 | 63篇 |
1999年 | 63篇 |
1998年 | 58篇 |
1997年 | 50篇 |
1996年 | 47篇 |
1995年 | 40篇 |
1994年 | 28篇 |
1993年 | 15篇 |
1992年 | 40篇 |
1991年 | 32篇 |
1990年 | 32篇 |
1989年 | 33篇 |
1988年 | 26篇 |
1987年 | 31篇 |
1986年 | 28篇 |
1985年 | 22篇 |
1984年 | 15篇 |
1983年 | 13篇 |
1981年 | 10篇 |
1979年 | 10篇 |
1977年 | 10篇 |
1976年 | 12篇 |
1973年 | 8篇 |
1972年 | 14篇 |
1970年 | 12篇 |
1969年 | 9篇 |
排序方式: 共有6690条查询结果,搜索用时 0 毫秒
31.
32.
33.
Emilie Savoye Camille Legeai Julien Branchereau Samuel Gay Bruno Riou Francois Gaudez Benoit Veber Franck Bruyere Gaelle Cheisson Thomas Kerforne Lionel Badet Olivier Bastien Corinne Antoine and the cDCD National Steering Committee 《American journal of transplantation》2021,21(7):2424-2436
Controlled donation after circulatory death (cDCD) is used for “extended criteria” donors with poorer kidney transplant outcomes. The French cDCD program started in 2015 and is characterized by normothermic regional perfusion, hypothermic machine perfusion, and short cold ischemia time. We compared the outcomes of kidney transplantation from cDCD and brain-dead (DBD) donors, matching cDCD and DBD kidney transplants by propensity scoring for donor and recipient characteristics. The matching process retained 442 of 499 cDCD and 809 of 6185 DBD transplantations. The DGF rate was 20% in cDCD recipients compared with 28% in DBD recipients (adjusted relative risk [aRR], 1.43; 95% confidence interval [CI] 1.12–1.82). When DBD transplants were ranked by cold ischemia time and machine perfusion use and compared with cDCD transplants, the aRR of DGF was higher for DBD transplants without machine perfusion, regardless of the cold ischemia time (aRR with cold ischemia time <18 h, 1.57; 95% CI 1.20–2.03, vs aRR with cold ischemia time ≥18 h, 1.79; 95% CI 1.31–2.44). The 1-year graft survival rate was similar in both groups. Early outcome was better for kidney transplants from cDCD than from matched DBD transplants with this French protocol. 相似文献
34.
Specific nutrition and metabolic characteristics of critically ill patients with persistent COVID-19
35.
Thierry Tiendrebeogo Eugne Messou Shino Arikawa Didier K Ekouevi Aristophane Tanon Vivian Kwaghe Eric Balestre Marcel Djimon Zannou Armel Poda Franois Dabis Antoine Jaquet Albert Minga Renaud Becquet IeDEA West Africa Collaboration 《Journal of the International AIDS Society》2021,24(5)
IntroductionSex differences have already been reported in sub‐Saharan Africa for attrition and immunological response after antiretroviral therapy (ART) initiation, but follow‐up was usually limited to the first two to three years after ART initiation. We evaluated sex differences on the same outcomes in the 10 years following ART initiation in West African adults.MethodsWe used cohort data of patients included in the IeDEA West Africa collaboration, who initiated ART between 2002 and 2014. We modelled no‐follow‐up and 10‐year attrition risks, and immunological response by sex using logistic regression analysis, survival analysis with random effect and linear mixed models respectively.ResultsA total of 71,283 patients (65.8% women) contributed to 310,007 person‐years of follow‐up in 16 clinics in eight West African countries. The cumulative attrition incidence at 10‐year after ART initiation reached 75% and 68% for men and women respectively. Being male was associated with an increased risk of no follow‐up after starting ART (5.1% vs. 4.0%, adjusted Odds Ratio: 1.25 [95% CI: 1.15 to 1.35]) and of 10‐year attrition throughout the 10‐year period following ART initiation: adjusted Hazard Ratios were 1.22 [95% CI: 1.17 to 1.27], 1.08 [95% CI: 1.04 to 1.12] and 1.04 [95% CI: 1.01 to 1.08] during year 1, years 2 to 4 and 5 to 10 respectively. A better immunological response was achieved by women than men: monthly CD4 gain was 30.2 and 28.3 cells/mL in the first four months and 2.6 and 1.9 cells/μL thereafter. Ultimately, women reached the average threshold of 500 CD4 cells/μL in their sixth year of follow‐up, whereas men failed to reach it even at the end of the 10‐year follow‐up period. The proportion of patients reaching the threshold was much higher in women than in men after 10 years since ART initiation (65% vs. 44%).ConclusionsIn West Africa, attrition is unacceptably high in both sexes. Men are more vulnerable than women on both attrition and immunological response to ART in the 10 years following ART initiation. Innovative tracing strategies that are sex‐adapted are needed for patients in care to monitor attrition, detect early high‐risk groups so that they can stay in care with a durably controlled infection. 相似文献
36.
Mouillet Guillaume Falcoz Antoine Fritzsch Joëlle Almotlak Hamadi Jacoulet Pascale Pivot Xavier Villanueva Cristian Mansi Laura Kim Stefano Curtit Elsa Meneveau Nathalie Adotevi Olivier Jary Marine Eberst Guillaume Vienot Angelique Calcagno Fabien Pozet Astrid Djoumakh Oumelkheir Borg Christophe Westeel Virginie Anota Amélie Paget-Bailly Sophie 《Quality of life research》2021,30(11):3255-3266
Quality of Life Research - Routine Electronic Monitoring of Health-Related Quality of Life (HRQoL) (REMOQOL) in clinical care with real-time feedback to physicians could help to enhance... 相似文献
37.
Antoine C Liebens F Carly B Pastijn A Rozenberg S;Women's Health Initiative 《Human reproduction (Oxford, England)》2004,19(3):741-756
INTRODUCTION: Mortality due to breast cancer has been reported to be the same or even lower in HRT users than in non-users. This has been attributed to earlier diagnosis and to better prognosis. Nevertheless, more advanced disease in HRT users was reported recently by the Women's Health Initiative (WHI) study. The objective of this study was to assess, using a systematic review of current literature, whether the data of the WHI study are in contradiction to observational data. METHODS: We selected 25 studies, for which we evaluated the methodology, the characteristics of the studied populations, confounding breast cancer risk factors and prognostic indicators. RESULTS: The WHI study, showing a worsening of some prognostic parameters, is in contradiction to most published observational studies. Most observational studies are retrospective, not well matched and did not consider most confounding factors. Their methodology and selection criteria varied considerably and the number of patients was often small. No differences in the distributions of histology, grade or steroid receptors were observed in the WHI trial, while this was the case in some of the observational studies. Other parameters (S phase, protein Neu, Bcl-2 gene, protein p53 and E-cadherin, cathepsin D) were not reported in the WHI trial. CONCLUSIONS: In view of these data, the current clinical message to patients should be changed: one can no longer declare that breast cancers developed while using HRT are of better prognosis. 相似文献
38.
Antoine JC Absi L Honnorat J Boulesteix JM de Brouker T Vial C Butler M De Camilli P Michel D 《Archives of neurology》1999,56(2):172-177
BACKGROUND: Antiamphiphysin antibodies react with a 128-kd protein found in synaptic vesicles.They were first described in patients with paraneoplastic stiff-man syndrome and breast cancer, but studies suggest that they can also occur in patients with other tumors and neurological disorders. OBJECTIVE: To determine if antiamphiphysin antibodies are associated with various paraneoplastic neurological syndromes and tumors. PATIENTS AND METHODS: Of 2800 serum samples tested by routine immunohistochemical procedures on sections of paraformaldehyde-fixed rat brain for the detection of autoantibodies associated with paraneoplastic neurological syndromes, 5 were selected because of labeling suggestive of antiamphiphysin antibodies and subsequently confirmed by the results of Western blot analysis using recombinant amphiphysin protein. Controls consisted of 40 patients with various nonparaneoplastic neurological diseases; 101 patients with cancer but without paraneoplastic neurological syndrome; 9 patients with small cell lung cancer, anti-Hu antibodies, and paraneoplastic neurological syndrome; 3 patients with M2-type antimitochondrial antibodies but no neurological disorder; and 30 normal subjects. RESULTS: Of the 5 patients with antiamphiphysin antibodies, patient 1 had sensory neuronopathy, encephalomyelitis, and breast cancer; patient 2 had limbic encephalitis, and small cell lung cancer was detected in the mediastinum after 24 months of follow-up; patient 3 had encephalomyelitis and ovarian carcinoma; and patients 4 and 5 had Lambert-Eaton myasthenic syndrome and small cell lung cancer (patient 4 subsequently developed cerebellar degeneration). None of the 5 had stiffness. Two patients (Nos. 2 and 4) had antimitochondrial antibodies. The two patients (Nos. 4 and 5) with Lambert-Eaton myasthenic syndrome had antibodies directed against the voltage-gated calcium channel, and patient 2 subsequently developed anti-Hu antibodies. In the controls, antiamphiphysin antibodies were detected by Western blot analysis in 3 of 8 patients with anti-Hu antibodies, but in none of the other groups. CONCLUSIONS: These data indicate that antiamphiphysin antibodies are not specific for one type of tumor or one neurological syndrome and can be associated with other neural and nonneural antibodies. The simultaneous association of several antibodies in some patients suggests multimodal autoantibody production. 相似文献
39.
Honnorat J Byk T Kusters I Aguera M Ricard D Rogemond V Quach T Aunis D Sobel A Mattei MG Kolattukudy P Belin MF Antoine JC 《The European journal of neuroscience》1999,11(12):4226-4232
Anti-CV2 autoantibodies have recently been discovered in patients with paraneoplastic neurological diseases (PND). These disorders are associated with neuronal degeneration, mediated by autoimmune processes, in patients with systemic cancer. Anti-CV2 autoantibodies recognize a brain protein of 66 kDa developmentally regulated and specifically expressed by a subpopulation of oligodendrocytes in the adult brain. Here, we demonstrate that anti-CV2 sera recognize several post-translationally modified forms of Ulip4/CRMP3, a member of a protein family related to the axonal guidance and homologous to the Unc-33 gene product in Caenorhabditis elegans. The sequence of the human Ulip4/CRMP3 was determined and the gene localized to chromosome 10q25.2-q26, a region mutated in glioblastomas and containing tumour suppressor genes. The identification of the Ulip/CRMP proteins as recognized by anti-CV2 sera should provide new insights into the role of Ulip/CRMPs in oligodendrocytes and into pathophysiology of PND. 相似文献
40.